Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profileg
Marcia Cruz-Correa, MD, PhD

@mcruzcorrea

Gastrointestinal Oncologist, Mother, Physician Scientist & CMO PanOncology Trials. Tweets are mine.

ID:2278325933

linkhttp://www.panoncologytrials.com calendar_today13-01-2014 04:37:16

652 Tweets

1,4K Followers

179 Following

Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Its a wrap amazing meeting full of energy, innovation, and strong science to increase health equity in our communities! THANK YOU Margaret Foti, PhD, MD (hc) and all organizers! Returning charged with ideas and many action items😆

Its a wrap #AACR24 amazing meeting full of energy, innovation, and strong science to increase health equity in our communities! THANK YOU @AACR_CEO and all organizers! Returning charged with ideas and many action items😆 #ClinicalTrials #HealthEquity
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

the ⁦Ciencias Médicas UPR⁩ ⁦Centro Comprensivo de Cancer UPR⁩ scientists who presented over 25 scientific posters and presentations covering the state of the sciences in cancer prevention, clinical trials participation, cancer genetics, microbiome, cancer disparities among 🇵🇷 Congrats!!

#aacr24 the ⁦@rcmupr⁩ ⁦@cccupr⁩ scientists who presented over 25 scientific posters and presentations covering the state of the sciences in cancer prevention, clinical trials participation, cancer genetics, microbiome, cancer disparities among #Hispanics🇵🇷 Congrats!!
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

excited to see our contribution to the Mirati Therapeutics clinical trial for patients with metastatic colon cancer. The OS was 16 months, with excellent safety profile. This is the new SOC for mCRC with G12C mutation and our Latino community had access to this trial

#AACR24 excited to see our contribution to the @Mirati clinical trial for patients with metastatic colon cancer. The OS was 16 months, with excellent safety profile. This is the new SOC for mCRC with #KRAS G12C mutation and our Latino community had access to this trial
account_circle
AACR(@AACR) 's Twitter Profile Photo

AACR Academy President Elizabeth M. Jaffee, MD, FAACR, introduces the newly inducted AACR Fellows to the delegates at the AACR Annual Meeting Opening Ceremony.
Dr. Elizabeth Jaffee

AACR Academy President Elizabeth M. Jaffee, MD, FAACR, introduces the newly inducted AACR Fellows to the #AACR24 delegates at the AACR Annual Meeting Opening Ceremony. #AACRFellows @DrLizJaffee
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Liver fibrosis/NASH is a highly prevalent global disease specially among Hispanics. Until March 2024 there were no approved drug to treat patients with and management have been focused on diet and exercise. Using the accelerated approval process FDA Approves First

account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Another year to celebrate life, continue our mission with passion to discover, improve health and empower the next generation!!! my dear friends for celebrating & being part of my tribe💗💗💗

Que siga la fiesta🥳🥳🥳🥂🥂🥂🇵🇷🇵🇷🇵🇷 Gracias al Creador que nos da vida🙏

Another year to celebrate life, continue our mission with passion to discover, improve health and empower the next generation!!! #Thankyou my dear friends for celebrating & being part of my tribe💗💗💗 Que siga la fiesta🥳🥳🥳🥂🥂🥂🇵🇷🇵🇷🇵🇷 Gracias al Creador que nos da vida🙏
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

The controversy of adding oxaliplatin to adjuvant therapy for older > 70 yrs old patients with Colorectal cancer was evaluated by Dottorini et al in JCO ⁦ASCO

The large meta analysis found no additional benefit of adding Oxaliplatin-based vs. 5-FU based CTX

The controversy of adding oxaliplatin to adjuvant therapy for older > 70 yrs old patients with Colorectal cancer was evaluated by Dottorini et al in JCO ⁦@ASCO⁩ The large meta analysis found no additional benefit of adding Oxaliplatin-based vs. 5-FU based CTX #coloncancer
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Learning about management of endoscopic submucosal tumors using full thickness resection. This technique allows for removal of the tumor via endoscopy. Dr. Mouen Khashab ⁦Johns Hopkins University⁩ presenting during ⁦gastropr PanOncology Trials

account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Congratulations to all around the world to contribute every day with their strength, wisdom & heart💗 We are blessed to have this mission of service 🇵🇷❤️ FDA Oncology PanOncology Trials AACR

Congratulations to all #womendoctors around the world to contribute every day with their strength, wisdom & heart💗 We are blessed to have this mission of service 🇵🇷❤️#NationalWomenPhysiciansDay @FDAOncology @panoncology @AACR
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

I want to share with you the beautiful journey of our Basketball 🏀 glory Piculin Ortiz, who was recently diagnosed with colorectal cancer and is opening up about faith & the process of treatment. We are honored to be in his corner💪🙏⁦PanOncology Trials⁩ metro.pr/opinion/2024/0…

account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

The controversy for addition of for patients with mCRC continues. This RCT with 5 year survival data found no added value for intraperitoneal chemotherapy compared to standard chemotherapy in reducing peritoneal metastasis. See @JCO report

Adjuvant Hyperthermic

account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Returning from ASCO⁩ meeting this weekend, amazing conference, great to see many friends, meet new collaborators and continue to bring the best clinical trials to ⁦PanOncology Trials⁩ for our Latin American patients!

Here is Wilson, waiting for mama🥰 ❤️

Returning from #GI24 ⁦@ASCO⁩ meeting this weekend, amazing conference, great to see many friends, meet new collaborators and continue to bring the best clinical trials to ⁦@panoncology⁩ for our Latin American patients! Here is Wilson, waiting for mama🥰 #schnauzer ❤️
account_circle
Marcia Cruz-Correa, MD, PhD(@mcruzcorrea) 's Twitter Profile Photo

Very exciting data for advanced tumors using radio pharmacological agent Lu-Dotatate as 1st line therapy in a large RCT demonstrating 👆PFS compared with SOC

This is paradigm changing for our patients with GI/Pancreas NET 🙌🧡 The ASCO Post PanOncology Trials

Very exciting data for advanced #neuroendocrine tumors using radio pharmacological agent Lu-Dotatate as 1st line therapy in a large RCT demonstrating 👆PFS compared with SOC This is paradigm changing for our patients with GI/Pancreas NET 🙌🧡 #GI24 @ASCOPost @panoncology
account_circle